Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos Therapeutics enters debt-to-equity exchange; receives Nasdaq bid price deficiency notice

Vivos Therapeutics, Inc.

Exchange agreement to convert up to $4.5M of Streeterville debt into non-convertible preferred and common stock, contingent on equity financings of at least $2.6M (first tranche) by June 15, 2026.
Streeterville suspends monthly principal redemptions until Sept 15, 2026; reduces monthly cap to $225K; extends note maturity to June 10, 2027.
Vivos issued V-Co Investors 4 LLC a $5M convertible note (initial $500K draw) to support proposed $5.5M equity financing expected by June 30, 2026.
Nasdaq notified Vivos on June 5, 2026, of non-compliance with $1.00 minimum bid price; 180-day cure period ends Dec 2, 2026.
Company also fails Nasdaq's $2.4M minimum stockholders' equity requirement; plans to cure via exchange agreement and equity raise.

item 1.01 item 2.03 item 3.01 item 3.02 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #2 for 2026-06-08. Read digest

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Vivos Therapeutics, Inc. incurred convertible notes of maximum principal amount of up to $5,000,000 with V-Co Investors 4 LLC at does not bear any interest.

Instrument: convertible notes
Principal: maximum principal amount of up to $5,000,000
Counterparty: V-Co Investors 4 LLC
Rate: does not bear any interest
Event: incurrence

Exact text from the filing

On May 7, 2026, the Company entered into an unsecured convertible promissory note in favor of V-Co Investors 4 LLC (“ V-Co 4 ”) in the maximum principal amount of up to $5,000,000

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 5, 2026, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Notice ”). The Notice has no immediate effect on the continued listing status of the Company’s Common Stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains

View on SEC.gov

289 debt financings filed in the last 30 days. Browse all debt financings →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-027641

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.